

RECEIVED
CENTRAL FAX CENTER

MAR 13 2007


Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A compound of the formula

(I):






and pharmaceutically acceptable salts thereof;

wherein:

A is R'-C(O)-, wherein R' is ~~selected from R¹-~~

~~C₁-C₆ alkyl;~~



7

or

;

each R¹ is independently selected from -C(O)-, -S(O)₂-,
-C(O)-C(O)-, -O-C(O)-, -O-S(O)₂-, -NR²-, -NR²-S(O)₂-, -NR²-C(O)-
or -NR²-C(O)-C(O)-;

each Ht is independently selected from C₃-C₇
cycloalkyl; C₅-C₇ cycloalkenyl; C₆-C₁₄ aryl; or a 5-7 membered

Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice

saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, N(R²), O, S and S(O)_n; wherein said aryl or said heterocycle is optionally fused to Q; and wherein any member of said Ht is optionally substituted with one or more substituents independently selected from oxo, -OR², SR², -R², -N(R²)(R²), -R²-OH, -CN, -CO₂R², -C(O)-N(R²)₂, -S(O)₂-N(R²)₂, -N(R²)-C(O)-R², -N(R²)-C(O)O-R², -C(O)-R², -S(O)_n-R², -OCF₃, -S(O)_n-Q, methylenedioxy, -N(R²)-S(O)₂(R²), halo, -CF₃, -NO₂, Q, -OQ, -OR⁷, -SR⁷, -R⁷, -N(R²)(R⁷) or -N(R⁷)₂;

each R² is independently selected from H, or C₁-C₄ alkyl optionally substituted with a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from O, N, S, S(O)_n or N(R³³); wherein any of said ring systems or N(R³³) is optionally substituted with 1 to 4 substituents independently selected from -X'-Y', -O-arylalkyl, -S-arylalkyl, -N(Y')₂, -N(H)-arylalkyl, -N(C₁-C₄ alkyl)-arylalkyl, oxo, -O-(C₁-C₄ alkyl), OH, C₁-C₄ alkyl, -SO₂H, -SO₂-(C₁-C₄ alkyl), -SO₂-NH₂, -SO₂-NH(C₁-C₄ alkyl), -SO₂-N(C₁-C₄ alkyl)₂, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -NH-C(O)H, -N(C₁-C₄ alkyl)-C(O)H, -NH-C(O)-C₁-C₄ alkyl, -C₁-C₄ alkyl-OH, -OH, -CN, -C(O)OH, -C(O)O-C₁-C₄ alkyl, -C(O)-NH₂, -C(O)-NH(C₁-C₄ alkyl), -C(O)-N(C₁-C₄ alkyl)₂, halo or -CF₃;

App'n. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice

X' is -O-, -S-, -NH-, -NHC(O)-, -NHC(O)O-, -NHSO₂-,
or -N(C₁-C₄)alkyl-;

Y' is C₁-C₁₅ alkyl, C₂-C₁₅ alkenyl or alkynyl, wherein
one to five carbon atoms in Y are optionally substituted with
C₁-C₇ cycloalkyl or C₅-C₆ cycloalkenyl, C₆-C₁₄ aryl or a 5-7
membered saturated or unsaturated heterocycle, containing one
or more heteroatoms selected from N, NH, O, S and S(O)_n;

each R³ is independently selected from H, Ht, C₁-C₆
alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl or C₅-C₆
cycloalkenyl; wherein any member of said R³, except H, is
optionally substituted with one or more substituents selected
from -OR², -C(O)-N(R²)₂, -S(O)_n-N(R²)₂, -N(R²)₂, -N(R²)-C(O)O(R²),
-N(R²)-C(O)N(R²)₂, -N(R²)-C(O)-R², Ht, -CN, -SR², -C(O)OR²,
N(R²)-C(O)-R²;

each R³³ is selected from H, C₁-C₆ alkyl, C₂-C₆
alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl or C₅-C₆ cycloalkenyl,
C₆-C₁₄ aryl or a 5-7 membered saturated or unsaturated
heterocycle, containing one or more heteroatoms selected from
N, NH, O, S and S(O)_n;

each n is independently 1 or 2;

G, when present, is selected from H, R⁷ or C₁-C₄
alkyl, or, when G is C₁-C₄ alkyl, G and R⁷ are bound to one
another either directly or through a C₁-C₃ linker to form a
heterocyclic ring; or

Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice

when G is not present (i.e., when x in (G)_x is 0), then the nitrogen to which G is attached is bound directly to the R⁷ group in -OR⁷ with the concomitant displacement of one -ZM group from R⁷;

D is selected from C₁-C₆ alkyl which is substituted with Q, which is optionally substituted with one or more groups selected from C₃-C₆ cycloalkyl, -R³, -O-Q or Q; C₂-C₄ alkenyl which is substituted with Q, which is optionally substituted with one or more groups selected from -OR³, -S-Ht, -R³, -O-Q or Q; C₃-C₆ cycloalkyl, which is optionally substituted with or fused to Q; or C₃-C₆ cycloalkenyl, which is optionally substituted with or fused to Q;

each Q is independently selected from a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from O, N, S, S(O)_n or N(R²); wherein Q contains one substituent selected from -OR², -OR⁸, -O-arylalkyl, -SR⁸, -S-arylalkyl, -N(R²)R⁸, -N(R²)-arylalkyl and may be optionally substituted with one or more additional substituents independently selected from oxo, -OR⁸, -O-arylalkyl -SR⁸, -S-arylalkyl, -N(R²)R⁸, -N(R²)-arylalkyl, -OR², -R², -SO₂R², -SO₂-N(R²)₂, -N(R²)₂, -N(R²)-C(O)-R², -OH, (C₁-C₄)-OH, -CN, -CO₂R², -C(O)-N(R²)₂, halo or -CF₃;

Appln. No. 10/691,333
 Reply dated March 13, 2007
 In response to February 12, 2007 Notice

each R^8 is independently selected from Ht, $-C_1-C_{15}$ branched or straight chain alkyl, alkenyl or alkynyl wherein one to five carbon atoms in said alkyl, alkenyl or alkynyl are independently replaced by W, or wherein one to five carbon atoms in said alkyl, alkenyl or alkynyl are substituted with Ht; and wherein R^8 is additionally and optionally substituted with one or more groups independently selected from $-OH$, $-S(C_1-C_6 \text{ alkyl})$, $-CN$, $-CF_3$, $-N(R^2)_2$, halo, $-C_1-C_4$ -alkyl, $-C_1-C_4$ -alkoxy; $-Ht$; $-O-Ht$; $-NR^2-CO-N(R^2)_2$; $-CO-N(R^2)_2$; $-R^1-C_2-C_6$ alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy, C_1-C_4 alkoxy, Ht, $-O-Ht$, $-NR^2-CO-N(R^2)_2$ or $-CO-N(R^2)_2$; or R^7 ;

wherein W is $-O-$, $-NR^2-$, $-S-$, $-C(O)-$, $-C(S)-$, $-C(=NR^2)-$, $-S(O)_2-$, $-NR^2-S(O)_2-$, $-S(O)_2-NR^2-$, $-NR^2-C(O)O-$, $-O-C(O)NR^2-$, $-NR^2-C(O)NR^2-$, $-NR^2-C(S)NR^2-$, $-CONR^2$, $-NR^2C(O)-$, $-C(S)NR^2$, $-NR^2C(S)-$, $-NR^2-C(=N-CN)-NR^2-$, $-NR^2C(=N-CN)O-$ or $-C(O)O-$;

D' is selected from C_1-C_{15} alkyl, C_1-C_{15} alkoxy, C_2-C_{15} alkenyl, C_2-C_{15} alkenyloxy, C_2-C_{15} alkynyl, or C_2-C_{15} alkynyloxy, wherein D' optionally comprises one or more substituents independently selected from Ht, oxo, halo, $-CF_3$, $-OCF_3$, $-NO_2$, azido, $-SH$, $-SR^3$, $-N(R^3)-N(R^3)_2$, $-O-N(R^3)_2$, $-(R^3)N-O-(R^3)$, $-N(R^3)_2$, $-CN$, $-CO_2R^3$, $-C(O)-N(R^3)_2$, $-S(O)_n-N(R^3)_2$, $-N(R^3)-C(O)-R^3$, $-N(R^3)-C(O)-N(R^3)_2$, $-C(O)-R^3$, $-S(O)_n-R^3$, $-N(R^3)-S(O)_n(R^3)$, $-N(R^3)-S(O)_n-N(R^3)_2$, $-S-NR^3-C(O)R^3$, $-C(S)N(R^3)_2$, $-C(S)R^3$,

Appln. No. 10/691,333
 Reply dated March 13, 2007
 In response to February 12, 2007 Notice


$-\text{NR}^3-\text{C}(\text{O})\text{OR}^3$, $-\text{O}-\text{C}(\text{O})\text{OR}^3$, $-\text{O}-\text{C}(\text{O})\text{N}(\text{R}^3)_2$, $-\text{NR}^3-\text{C}(\text{S})\text{R}^3$, $=\text{N}-\text{OH}$,
 $=\text{N}-\text{OR}^3$, $=\text{N}-\text{N}(\text{R}^3)_2$, $=\text{NR}^3$, $=\text{NNR}^3\text{C}(\text{O})\text{N}(\text{R}^3)_2$, $=\text{NNR}^3\text{C}(\text{O})\text{OR}^3$,
 $=\text{NNR}^3\text{S}(\text{O})_n-\text{N}(\text{R}^3)_2$, $-\text{NR}^3-\text{C}(\text{S})\text{OR}^3$, $-\text{NR}^3-\text{C}(\text{S})\text{N}(\text{R}^3)_2$,
 $-\text{NR}^3-\text{C}[\text{=N}(\text{R}^3)]-\text{N}(\text{R}^3)_2$, $-\text{N}(\text{R}^3)-\text{C}[\text{=N}-\text{NO}_2]-\text{N}(\text{R}^3)_2$,
 $-\text{N}(\text{R}^3)-\text{C}[\text{=N}-\text{NO}_2]-\text{OR}^3$, $-\text{OC}(\text{O})\text{R}^3$, $-\text{OC}(\text{S})\text{R}^3$, $-\text{OC}(\text{O})\text{N}(\text{R}^3)_2$,
 $-\text{C}(\text{O})\text{N}(\text{R}^3)-\text{N}(\text{R}^3)_2$, $-\text{N}(\text{R}^3)-\text{N}(\text{R}^3)\text{C}(\text{O})\text{R}^3$, $-\text{N}(\text{R}^3)-\text{OC}(\text{O})\text{R}^3$,
 $-\text{N}(\text{R}^3)-\text{OC}(\text{O})\text{R}^3$, $-\text{N}(\text{R}^3)-\text{OC}(\text{O})\text{R}^3$, $-\text{OC}(\text{S})\text{N}(\text{R}^3)_2$, $-\text{OC}(\text{S})\text{N}(\text{R}^3)(\text{R}^3)$, or
 $-\text{PO}_3-\text{R}^3$;

E is selected from Ht; O-Ht; Ht-Ht; Ht fused with Ht; $-\text{O}-\text{R}^3$; $-\text{N}(\text{R}^2)(\text{R}^3)$; $-\text{N}(\text{R}^2)-\text{Ht}$; C_1-C_6 alkyl, which is optionally substituted with one or more groups selected from R^4 or Ht; C_2-C_6 alkenyl, which is optionally substituted with one or more groups selected from R^4 or Ht; C_3-C_6 saturated carbocycle, which is optionally substituted with one or more groups selected from R^4 or Ht; or C_5-C_6 unsaturated carbocycle, which is optionally substituted with one or more groups selected from R^4 or Ht;

each R^4 is independently selected from $-\text{R}^2$, $-\text{OR}^2$, $-\text{OR}^3$, $-\text{SR}^2$, $-\text{SOR}^2$, $-\text{SO}_2\text{R}^2$, $-\text{CO}_2\text{R}^2$, $-\text{OC}(\text{O})-\text{R}^2$, $-\text{C}(\text{O})-\text{N}(\text{R}^2)_2$, $-\text{C}(\text{O})-\text{NR}^3(\text{OR}^2)$, $-\text{S}(\text{O})_2-\text{N}(\text{R}^2)_2$, halo, $-\text{NR}^2-\text{C}(\text{O})-\text{R}^2$, $-\text{NR}^2-\text{OR}^2$, $-\text{N}(\text{R}^2)_2$ or $-\text{CN}$;

each R^7 is independently selected from hydrogen,

Appin. No. 10/641,333
 Reply dated March 13, 2007
 In response to February 12, 2007 Notice



wherein each M is independently selected from H, Li, Na, K, Mg, Ca, Ba, $\text{---N(R}^2\text{)}_4$, $\text{C}_1\text{---C}_{12}\text{---alkyl}$, $\text{C}_2\text{---C}_{12}\text{---alkenyl}$, or ---R^6 ; wherein 1 to 4 ---CH_2 radicals of the alkyl or alkenyl group, other than the ---CH_2 that is bound to Z, is optionally replaced by a heteroatom group selected from O, S, S(O) , S(O)_2 , or $\text{N(R}^2\text{)}$; and wherein any hydrogen in said alkyl, alkenyl or R^6 is optionally replaced with a substituent selected from oxo, $\text{---C}_1\text{---C}_4$ alkyl, $\text{---N(R}^2\text{)}_2$, $\text{---N(R}^2\text{)}_3$, ---OH , $\text{---O---(C}_1\text{---C}_4\text{ alkyl)}$, ---CN , ---C(O)OR^2 , $\text{---C(O)---N(R}^2\text{)}_2$, $\text{S(O)}_2\text{---N(R}^2\text{)}_2$, $\text{---N(R}^2\text{)---C(O)---R}_2$, C(O)R^2 , $\text{---S(O)}_n\text{---R}^2$, ---OCF_3 , $\text{---S(O)}_n\text{---R}^6$, $\text{---N(R}^2\text{)---S(O)}_2\text{(R}^2\text{)}$, halo, ---CF_3 , or ---NO_2 ;

M' is H, $\text{C}_1\text{---C}_{12}\text{---alkyl}$, $\text{C}_2\text{---C}_{12}\text{---alkenyl}$, or ---R^6 ; wherein 1 to 4 ---CH_2 radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected from O, S, S(O) , S(O)_2 , or $\text{N(R}^2\text{)}$; and wherein any hydrogen in said alkyl, alkenyl or R^6 is optionally replaced with a substituent selected from oxo, ---OR^2 , $\text{---C}_1\text{---C}_4$ alkyl, $\text{---N(R}^2\text{)}_2$, $\text{N(R}^2\text{)}_3$, ---OH , $\text{---O---(C}_1\text{---C}_4\text{ alkyl)}$, ---CN , ---C(O)OR^2 , $\text{---C(O)---N(R}^2\text{)}_2$, $\text{---S(O)}_2\text{---N(R}^2\text{)}_2$, $\text{---N(R}^2\text{)---C(O)---R}_2$, ---C(O)R^2 , $\text{---S(O)}_n\text{---R}^2$, ---OCF_3 , $\text{---S(O)}_n\text{---R}^6$, $\text{---N(R}^2\text{)---S(O)}_2\text{(R}^2\text{)}$, halo, ---CF_3 , or ---NO_2 ;

x is 0 or 1;

Z is O, S, $\text{N(R}^2\text{)}_2$, or, when M is not present, H;

Appin. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice

Y is P or S;

X is O or S; and

R^9 is $C(R^3)_2$, O or $N(R^2)$; and wherein when Y is S, Z is not S; and

R^6 is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered saturated, partially saturated or unsaturated bicyclic ring system; wherein any of said heterocyclic ring systems contains one or more heteroatoms selected from O, N, S, $S(O)_n$ or $N(R^2)$; and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from -OH, $-C_1-C_4$ alkyl, $-O-(C_1-C_4 \text{ alkyl})$ or $-O-C(O)-(C_1-C_4 \text{ alkyl})$.

2. (Original) The compound according to claim 1, wherein R^8 is $-C_1-C_4$ -branched or straight chain alkyl, wherein one to two carbon atoms in said alkyl are independently replaced by W, wherein R^8 is additionally and optionally substituted with one or more groups independently selected from -OH; $-C_1-C_4$ -alkoxy; -Ht; -O-Ht; $-NR^2-CO-N(R^2)_2$; $-CO-N(R^2)_2$; $-R^1-C_2-C_6$ alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy, C_1-C_4 alkoxy, Ht, -O-Ht, $-NR^2-CO-N(R^2)_2$ or $-CO-N(R^2)_2$; or R^7 ; wherein W is -O-, $-NR^2$ -, $-NR^2-S(O)_2$ -, $-NR^2-C(O)O$ -.

Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice


$-O-C(O)NR^2-$, $-NR^2-C(O)NR^2-$, $-NR^2-C(S)NR^2-$, $-NR^2C(O)-$, $-C(=NR^2)-$,
 $-C(O)NR^2-$, $-NR^2-C(=N-CN)-NR^2-$, $-NR^2C(=N-CN)O-$ or $-C(O)O-$; and
wherein Ht, R^1 , R^2 and R^7 are as defined in claim 1.

3. (Previously presented) The compound according to claim 1, wherein R^8 is a $-C_1-C_4$ -branched or straight alkyl chain, wherein one to two carbon atoms are substituted with Ht;


wherein Ht is C_{6-14} aryl or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, $N(R^2)$, O, S and $S(O)_n$, wherein any member of Ht is optionally substituted with one or more substituents independently selected from oxo, $-OR^2$, SR^2 , $-R^2$, $-N(R^2)(R^2)$, $-R^2-OH$, $-CN$, $-CO_2R^2$, $-C(O)-N(R^2)_2$, $-S(O)_2-N(R^2)_2$, $-N(R^2)-C(O)-R^2$, $-N(R^2)-C(O)O-R^2$, $-C(O)-R^2$, $-S(O)_n-R^2$, $-OCF_3$, $-S(O)_n-Q$, methylenedioxy, $-N(R^2)-S(O)_2(R^2)$, halo, $-CF_3$, $-NO_2$, Q, $-OQ$, $-OR^7$, $-SR^7$, $-R^7$, $-N(R^2)(R^7)$ or $-N(R^7)_2$.

4. (Currently amended) The compound according to claim 1, wherein R^8 is selected from:


Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice




Appln. No. 10/691,333
 Reply dated March 13, 2007
 In response to February 12, 2007 Notice



5. (Original) The compound according to claim 1,
 wherein at least one R⁷ is selected from:



Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice




6. {Canceled}.

Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice

7. (Currently amended) The compound according to claim 1, wherein:


D' is $-\text{CH}_2-\text{R}'$, wherein R' is selected from:
isobutyl,;



wherein m is 0 to 3.

8. (Previously presented) The compound according to claim 1, wherein:


E is selected from:



9. (Currently amended) A compound having the

Appln. No. 10/691,333
 Reply dated March 13, 2007
 In response to February 12, 2007 Notice


formula (II):




and pharmaceutically acceptable salts thereof;

wherein:


A is selected from R'-C(O)-, wherein R' is selected
~~from R¹-C₁-C₆-alkyl,~~



[[,]]



or



;

each R¹ is independently selected from -C(O)-,
 -S(O)₂-, -C(O)-C(O)-, -O-C(O)-, -O-S(O)₂-, -NR²-, -NR²-S(O)₂-,
 -NR²-C(O)- or -NR²-C(O)-C(O)-;

each Ht is independently selected from C₃-C₇
 cycloalkyl; C₅-C₇ cycloalkenyl; C₆-C₁₄ aryl; or a 5-7 membered
 saturated or unsaturated heterocycle, containing one or more
 heteroatoms selected from N, N(R³), O, S and S(O)_n; wherein
 said aryl or said heterocycle is optionally fused to Q; and

App'n. No. 10/691,333
 Reply dated March 13, 2007
 In response to February 12, 2007 Notice

wherein any member of said Ht is optionally substituted with one or more substituents independently selected from oxo, $-OR^2$, SR^2 , $-R^2$, $-N(R^2)(R^2)$, $-R^2-OH$, $-CN$, $-CO_2R^2$, $-C(O)-N(R^2)_2$, $-S(O)_2-N(R^2)_2$, $-N(R^2)-C(O)-R^2$, $-N(R^2)-C(O)O-R^2$, $-C(O)-R^2$, $-S(O)_n-R^2$, $-OCF_3$, $-S(O)_n-Q$, methylenedioxy, $-N(R^2)-S(O)_2(R^2)$, halo, $-CF_3$, $-NO_2$, Q , $-OQ$, $-OR^7$, $-SR^7$, $-R^7$, $-N(R^2)(R^7)$ or $-N(R^7)_2$;

each R^2 is independently selected from H, or C_1-C_4 alkyl optionally substituted with a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from O, N, S, $S(O)_n$ or $N(R^{33})$; wherein any of said ring systems or $N(R^{33})$ is optionally substituted with 1 to 4 substituents independently selected from $-X'-Y'$, $-O$ -arylalkyl,

$-S$ -arylalkyl, $-N(Y')_2$, $-N(H)$ -arylalkyl, $-N(C_1-C_4$ alkyl)-arylalkyl, oxo, $-O-(C_1-C_4$ alkyl), OH , C_1-C_4 alkyl, $-SO_2H$, $-SO_2-(C_1-C_4$ alkyl), $-SO_2-NH_2$, $-SO_2-NH(C_1-C_4$ alkyl), $-SO_2-N(C_1-C_4$ alkyl) $_2$, $-NH_2$, $-NH(C_1-C_4$ alkyl), $-N(C_1-C_4$ alkyl) $_2$, $-NH-C(O)H$, $-N(C_1-C_4$ alkyl)- $C(O)H$, $-NH-C(O)-C_1-C_4$ alkyl, $-C_1-C_4$ alkyl- OH , $-OH$, $-CN$, $-C(O)OH$, $-C(O)O-C_1-C_4$ alkyl, $-C(O)-NH_2$, $-C(O)-NH(C_1-C_4$ alkyl), $-C(O)-N(C_1-C_4$ alkyl) $_2$, halo or $-CF_3$;

X' is $-O-$, $-S-$, $-NH-$, $-NHC(O)-$, $-NHC(O)O-$, $-NHOSO_2-$, or $-N(C_1-C_4)$ alkyl-;

Y' is C_1-C_{15} alkyl, C_2-C_{15} alkenyl or alkynyl, wherein

Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice

one to five carbon atoms in Y are optionally substituted with C₃-C₇ cycloalkyl or C₅-C₆ cycloalkenyl, C₆-C₁₄ aryl or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, NH, O, S and S(O)_n;

each R³ is independently selected from H, Ht, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl or C₅-C₆ cycloalkenyl; wherein any member of said R³, except H, is optionally substituted with one or more substituents selected from -OR², -C(O)-N(R²)₂, -S(O)_n-N(R²)₂, -N(R²)₂, -N(R²)-C(O)O(R²), -N(R²)-C(O)N(R²)₂, -N(R²)-C(O)-R², Ht, -CN, -SR², -C(O)OR², N(R²)-C(O)-R²;

each R³³ is selected from H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl or C₅-C₆ cycloalkenyl, C₆-C₁₄ aryl or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, NH, O, S and S(O)_n;

each n is independently 1 or 2;

each Q is independently selected from a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from O, N, S, S(O)_n or N(R²); wherein Q contains one substituent selected from -OR², -OR⁸, -O-arylalkyl, -SR⁸, -S-arylalkyl, -N(R²)R⁸, -N(R²)-arylalkyl and

Appin. No. 10/691,333
 Reply dated March 13, 2007
 in response to February 12, 2007 Notice

may be optionally substituted with one or more additional substituents independently selected from oxo, $-OR^8$, $-O$ -arylalkyl $-SR^8$, $-S$ -arylalkyl, $-N(R^2)R^8$, $-N(R^2)$ -arylalkyl, $-OR^2$, $-R^2$, $-SO_2R^2$, $-SO_2-N(R^2)_2$, $-N(R^2)_2$, $-N(R^2)-C(O)-R^2$, $-OH$, $(C_1-C_4)-OH$, $-CN$, $-CO_2R^2$, $-C(O)-N(R^2)_2$, halo or $-CF_3$;

each R^8 is independently selected from Ht, $-C_1-C_{15}$ branched or straight chain alkyl, alkenyl or alkynyl wherein one to five carbon atoms in said alkyl, alkenyl or alkynyl are independently replaced by W, or wherein one to five carbon atoms in said alkyl, alkenyl or alkynyl are substituted with Ht; and wherein R^8 is additionally and optionally substituted with one or more groups independently selected from $-OH$, $-S(C_1-C_6 \text{ alkyl})$, $-CN$, $-CF_3$, $-N(R^2)_2$, halo, $-C_1-C_4$ -alkyl, $-C_1-C_4$ -alkoxy; $-Ht$; $-O-Ht$; $-NR^2-CO-N(R^2)_2$; $-CO-N(R^2)_2$; $-R^1-C_2-C_6$ alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy, C_1-C_4 alkoxy, Ht, $-O-Ht$, $-NR^2-CO-N(R^2)_2$ or $-CO-N(R^2)_2$; or R^7 ;

wherein W is $-O-$, $-NR^2-$, $-S-$, $-C(O)-$, $-C(S)-$, $-C(=NR^2)-$, $-S(O)_2-$, $-NR^2-S(O)_2-$, $-S(O)_2-NR^2-$, $-NR^2-C(O)O-$, $-O-C(O)NR^2-$, $-NR^2-C(O)NR^2-$, $-NR^2-C(S)NR^2-$, $-CONR^2$, $-NR^2C(O)-$, $-C(S)NR^2$, $-NR^2C(S)-$, $-NR^2-C(=N-CN)-NR^2-$, $-NR^2C(=N-CN)O-$ or $-C(O)O-$;

D' is selected from C_1-C_{15} alkyl, C_1-C_{15} alkoxy, C_2-C_{15} alkenyl, C_2-C_{15} alkenyloxy, C_2-C_{15} alkynyl, or C_2-C_{15} alkynyloxy, wherein D' optionally comprises one or more substituents

Appln. No. 10/691,333
 Reply dated March 13, 2007
 In response to February 12, 2007 Notice

independently selected from Ht, oxo, halo, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{NO}_2$, azido, $-\text{SH}$, $-\text{SR}^1$, $-\text{N}(\text{R}^3)-\text{N}(\text{R}^3)_2$, $-\text{O}-\text{N}(\text{R}^3)_2$, $-(\text{R}^3)\text{N}-\text{O}-(\text{R}^3)$, $-\text{N}(\text{R}^3)_2$, $-\text{CN}$, $-\text{CO}_2\text{R}^3$, $-\text{C}(\text{O})-\text{N}(\text{R}^3)_2$, $-\text{S}(\text{O})_n-\text{N}(\text{R}^3)_2$, $-\text{N}(\text{R}^3)-\text{C}(\text{O})-\text{R}^3$, $-\text{N}(\text{R}^3)-\text{C}(\text{O})-\text{N}(\text{R}^3)_2$, $-\text{C}(\text{O})-\text{R}^3$, $-\text{S}(\text{O})_n-\text{R}^3$, $-\text{N}(\text{R}^3)-\text{S}(\text{O})_n(\text{R}^3)$, $-\text{N}(\text{R}^3)-\text{S}(\text{O})_n-\text{N}(\text{R}^3)_2$, $-\text{S}-\text{NR}^3-\text{C}(\text{O})\text{R}^3$, $-\text{C}(\text{S})\text{N}(\text{R}^3)_2$, $-\text{C}(\text{S})\text{R}^3$, $-\text{NR}^3-\text{C}(\text{O})\text{OR}^3$, $-\text{O}-\text{C}(\text{O})\text{OR}^3$, $-\text{O}-\text{C}(\text{O})\text{N}(\text{R}^3)_2$, $-\text{NR}^3-\text{C}(\text{S})\text{R}^3$, $=\text{N}-\text{OH}$, $=\text{N}-\text{OR}^3$, $=\text{N}-\text{N}(\text{R}^3)_2$, $=\text{NR}^3$, $=\text{NNR}^3\text{C}(\text{O})\text{N}(\text{R}^3)_2$, $=\text{NNR}^3\text{C}(\text{O})\text{OR}^3$, $=\text{NNR}^3\text{S}(\text{O})_n-\text{N}(\text{R}^3)_2$, $-\text{NR}^3-\text{C}(\text{S})\text{OR}^3$, $-\text{NR}^3-\text{C}(\text{S})\text{N}(\text{R}^3)_2$, $-\text{NR}^3-\text{C}[\text{N}(\text{R}^3)]-\text{N}(\text{R}^3)_2$, $-\text{N}(\text{R}^3)-\text{C}[\text{N}-\text{NO}_2]-\text{N}(\text{R}^3)_2$, $-\text{N}(\text{R}^3)-\text{C}[\text{N}-\text{NO}_2]-\text{OR}^3$, $-\text{OC}(\text{O})\text{R}^3$, $-\text{OC}(\text{S})\text{R}^3$, $-\text{OC}(\text{O})\text{N}(\text{R}^3)_2$, $-\text{C}(\text{O})\text{N}(\text{R}^3)-\text{N}(\text{R}^3)_2$, $-\text{N}(\text{R}^3)-\text{N}(\text{R}^3)\text{C}(\text{O})\text{R}^3$, $-\text{N}(\text{R}^3)-\text{OC}(\text{O})\text{R}^3$, $-\text{N}(\text{R}^3)-\text{OC}(\text{O})\text{R}^3$, $-\text{N}(\text{R}^3)-\text{OC}(\text{O})\text{R}^3$, $-\text{OC}(\text{S})\text{N}(\text{R}^3)_2$, $-\text{OC}(\text{S})\text{N}(\text{R}^3)(\text{R}^3)$, or $-\text{PO}_3-\text{R}^3$;


E is selected from Ht; O-Ht; Ht-Ht; Ht fused with Ht; $-\text{O}-\text{R}^3$; $-\text{N}(\text{R}^2)(\text{R}^3)$; $-\text{N}(\text{R}^2)-\text{Ht}$; C_1-C_6 alkyl, which is optionally substituted with one or more groups selected from R^4 or Ht; C_2-C_6 alkenyl, which is optionally substituted with one or more groups selected from R^4 or Ht; C_3-C_6 saturated carbocycle, which is optionally substituted with one or more groups selected from R^4 or Ht; or C_5-C_6 unsaturated carbocycle, which is optionally substituted with one or more groups selected from R^4 or Ht;

each R^4 is independently selected from $-\text{R}^2$, $-\text{OR}^2$, $-\text{OR}^3$, $-\text{SR}^2$, $-\text{SOR}^2$, $-\text{SO}_2\text{R}^2$, $-\text{CO}_2\text{R}^2$, $-\text{OC}(\text{O})-\text{R}^2$, $-\text{C}(\text{O})-\text{N}(\text{R}^2)_2$,

Appln. No. 10/691,333
 Reply dated March 13, 2007
 In response to February 12, 2007 Notice

$-\text{C}(\text{O})-\text{NR}^2(\text{OR}^2)$, $-\text{S}(\text{O})_2-\text{N}(\text{R}^2)_2$, halo, $-\text{NR}^2-\text{C}(\text{O})-\text{R}^2$, $-\text{NR}^2-\text{OR}^2$,
 $-\text{N}(\text{R}^2)_2$ or $-\text{CN}$;

each R^7 is independently selected from hydrogen,



wherein each M is independently selected from H, Li, Na, K, Mg, Ca, Ba, $-\text{N}(\text{R}^2)_4$, C_1 - C_{12} -alkyl, C_2 - C_{12} -alkenyl, or $-\text{R}^6$; wherein 1 to 4 $-\text{CH}_2$ radicals of the alkyl or alkenyl group, other than the $-\text{CH}_2$ that is bound to Z, is optionally replaced by a heteroatom group selected from O, S, $\text{S}(\text{O})$, $\text{S}(\text{O}_2)$, or $\text{N}(\text{R}^2)$; and wherein any hydrogen in said alkyl, alkenyl or R^6 is optionally replaced with a substituent selected from oxo, $-\text{C}_1$ - C_4 alkyl, $-\text{N}(\text{R}^2)_2$, $-\text{N}(\text{R}^2)_3$, $-\text{OH}$, $-\text{O}-(\text{C}_1-\text{C}_4 \text{ alkyl})$, $-\text{CN}$, $-\text{C}(\text{O})\text{OR}^2$, $-\text{C}(\text{O})-\text{N}(\text{R}^2)_2$, $\text{S}(\text{O})_2-\text{N}(\text{R}^2)_2$, $-\text{N}(\text{R}^2)-\text{C}(\text{O})-\text{R}^2$, $\text{C}(\text{O})\text{R}^2$, $-\text{S}(\text{O})_n-\text{R}^2$, $-\text{OCF}_3$, $-\text{S}(\text{O})_n-\text{R}^6$, $-\text{N}(\text{R}^2)-\text{S}(\text{O})_2(\text{R}^2)$, halo, $-\text{CF}_3$, or $-\text{NO}_2$;

M' is H, C_1 - C_{12} -alkyl, C_2 - C_{12} -alkenyl, or $-\text{R}^6$; wherein 1 to 4 $-\text{CH}_2$ radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected from O, S, $\text{S}(\text{O})$, $\text{S}(\text{O}_2)$, or $\text{N}(\text{R}^2)$; and wherein any hydrogen in said alkyl, alkenyl or R^6 is optionally replaced with a substituent selected from oxo, $-\text{OR}^2$, $-\text{C}_1$ - C_4 alkyl, $-\text{N}(\text{R}^2)_2$, $\text{N}(\text{R}^2)_3$, $-\text{OH}$,

Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice

-O-(C₁-C₄ alkyl), -CN, -C(O)OR², -C(O)-N(R²)₂, -S(O)₂-N(R²)₂,
-N(R²)-C(O)-R₂, -C(O)R², -S(O)_n-R², -OCF₃, -S(O)_n-R⁶,
-N(R²)-S(O)₂(R²), halo, -CF₃, or -NO₂;

x is 0 or 1;

Z is O, S, N(R²)₂, or, when M is not present, H;

Y is P or S;


X is O or S; and

R⁹ is C(R²)₂, O or N(R²); and wherein when Y is S, Z
is not S; and


R⁶ is a 5-6 membered saturated, partially saturated
or unsaturated carbocyclic or heterocyclic ring system, or an
8-10 membered saturated, partially saturated or unsaturated
bicyclic ring system; wherein any of said heterocyclic ring
systems contains one or more heteroatoms selected from O, N,
S, S(O)_n or N(R²); and wherein any of said ring systems
optionally contains 1 to 4 substituents independently selected
from -OH, -C₁-C₄ alkyl, -O-(C₁-C₄ alkyl) or -O-C(O)-(C₁-C₄
alkyl).

10. (Original) The compound according to claim 9,
wherein R⁸ is selected from:

Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice




11. (Original) The compound according to claim 9,
wherein R⁸ is selected from:




12. (Original) The compound according to claim 9,

Appin. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice


wherein R^8 is selected from:




13. (Original) The compound according to claim 9,
wherein R^8 is selected from:



Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice



14. (Currently amended) The compound according to claim 9, wherein Rⁿ is selected from:



Appin. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice

15. (Currently amended) The compound according to claim 9, wherein said compound is selected from compound numbers: ~~22, 24, 25,~~ 26, 27, 31, 33, 35, 36, 38, 41, 43, 48, 49, 51, 52, 53, 54, 55, 56, 57, 59, 60, ~~69,~~ 71, 72, 73, 74, 202, 203, 209, 213, 215, 223, 227, 231, 233, 236, 237, 239, 243, 247, 250, 260, 263, 271, 281, 289, 293, 295, 309, 317, 319, 320, 322, 334, 335, 348, 364, 367, 368, 375, 382, 383 and 396.

16. (Currently amended) The compound according to claim 15, wherein said compound is selected from compound numbers: 26, 27, 31, 33, 35, 36, 38, 41, 43, 48, 49, 51, 52, 53, 54, 55, 56, 57, 59, 60, ~~69,~~ 71, 72, 73, 74, 209, 215, 227, 233, 237, 281, 289, 295, 309, 322, 335, 364, 368, 382 and 383.

17. (Previously presented) The compound according to claim 16, wherein said compound is selected from: 54, 209, 237, 281, 295, 309, and 368.

18. (Previously presented) A composition comprising a compound according to claim 1 or 9, in an amount sufficient to inhibit an aspartyl protease; and a pharmaceutically acceptable carrier.

Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice

19. (Original) The composition according to claim 18, wherein said composition is in a pharmaceutically acceptable form for administration to a human being.

20. (Original) The composition according to claim 18, wherein said composition additionally comprises an additional anti-viral agent.

21. (Original) The composition according to claim 18, wherein said composition comprises at least one additional therapeutic agent selected from (1 alpha, 2 beta, 3 alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]- guanine [(-)BHCG, SQ-34514]; oxetanocin-G (3,4-bis-(hydroxymethyl)-2-oxetanosyl]guanine); acyclic nucleosides, such as acyclovir, valaciclovir, famciclovir, ganciclovir or penciclovir; acyclic nucleoside phosphonates, such as (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC); ribonucleotide reductase inhibitors, such as 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl] thiocarbonohydrazone, 3'-azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides such as 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, or 2',3'-didehydrothymidine; other aspartyl protease inhibitors, such as indinavir, ritonavir, nelfinavir, or [3S-[3R*(1R*, 2S*)]]-[3[[[(4-aminophenyl)sulfonyl](2-

Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice

methylpropyl)aminol-2-hydroxy-1-(phenylmethyl)propyl]-
tetrahydro-3-furanyl ester (amprenavir); oxathiolane
nucleoside analogues, such as (-)-cis-1-(2-hydroxymethyl)-1,3-
oxathiolane 5-yl)-cytosine (lamivudine) or cis-1-(2-
(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC);
3'-deoxy-3'-fluorothymidine; 5-chloro-2',3'-dideoxy-3'-
fluorouridine; (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-
purin-9-yl]-2-cyclopentene-1-methanol; ribavirin; 9-[4-
hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G); tat
inhibitors, such as 7-chloro-5-(2-pyrrolyl)-3H-1,4-
benzodiazepin-2-(H)one (Ro5-3335) or 7-chloro-1,3-dihydro-5-
(1H-pyrrol-2yl)-3H-1,4-benzodiazepin-2-amine (Ro24-7429);
interferons, such as α -interferon; renal excretion inhibitors
such as probenecid; nucleoside transport inhibitors such as
dipyridamole; pentoxifylline; N-acetylcysteine (NAC);
Procysteine; α -trichosanthin; phosphonoformic acid;
immunomodulators, such as interleukin II or thymosin;
granulocyte macrophage colony stimulating factors;
erythropoietin; soluble CD₄ and genetically engineered
derivatives thereof; non-nucleoside reverse transcriptase
inhibitors (NNRTIs), such as nevirapine (BI-RG-587), loviride
(α -APA) or delavuridine (BHAP); phosphonoformic acid; 1,4-
dihydro-2H-3,1-benzoxazin-2-ones NNRTIs, such as (-)-6-chloro-

Appin. No. 10/691,333
Reply dated March 13, 2007
in response to February 12, 2007 Notice

4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); or quinoxaline NNRTIs, such as isopropyl (2S)-7-fluoro-3,4-dihydro-2-ethyl-3-oxo-1(2H)-quinoxalinecarboxylate (HBY1293).

22. (Previously presented) The composition according to claim 18, wherein said composition is in an orally available dosage form.

23. (Withdrawn) A method of treating a patient infected with a virus that depends upon an aspartyl protease for an obligatory event in its life cycle comprising the step of administering to said patient a composition according to claim 18.

24. (Withdrawn) A method of treating a patient infected with HIV-I or HIV-II comprising the step of administering to said patient a composition according to claim 18.

25. (Withdrawn) The method according to claim 23, comprising the additional step of administering to said patient an additional therapeutic agent selected from (1 alpha, 2 beta, 3 alpha)-9-[2,3-bis(hydroxymethyl)

Appln. No. 10/691,333
Reply dated March 13, 2007
in response to February 12, 2007 Notice

cyclobutyl]guanine [(-)BHCG, SQ-34514]; oxetanocin-G (3,4-bis-(hydroxymethyl)-2-oxetanosyl]guanine); acyclic nucleosides, such as acyclovir, valaciclovir, famciclovir, ganciclovir or penciclovir; acyclic nucleoside phosphonates, such as (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC); ribonucleotide reductase inhibitors, such as 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl] thiocarbonohydrazone, 3'-azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides such as 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, or 2',3'-didehydrothymidine; other aspartyl protease inhibitors, such as indinavir, ritonavir, nelfinavir, or [3S-[3R*(1R*, 2S*)]]-[3[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-tetrahydro-3-furanyl ester (amprenavir); oxathiolane nucleoside analogues, such as (-)-cis-1-(2-hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine (lamivudine) or cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC); 3'-deoxy-3'-fluorothymidine; 5-chloro-2',3'-dideoxy-3'-fluorouridine; (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ribavirin; 9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G); tat inhibitors, such as 7-chloro-5-(2-pyrryl)-3H-1,4-benzodiazepin-2-(H)one (Ro5-3335) or 7-chloro-1,3-dihydro-5-(1H-pyrrol-2yl)-3H-1,4-benzodiazepin-2-amine (Ro24-7429);

Appln. No. 10/691,333
Reply dated March 13, 2007
in response to February 12, 2007 Notice

interferons, such as α -interferon; renal excretion inhibitors such as probenecid; nucleoside transport inhibitors such as dipyrnidamole; pentoxifylline; N-acetylcysteine (NAC); Procysteine; α -trichosanthin; phosphonoformic acid; immunomodulators, such as interleukin II or thymosin; granulocyte macrophage colony stimulating factors; erythropoetin; soluble CD₄ and genetically engineered derivatives thereof; non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine (BI-RG-587), loviride (α -APA) or delavuridine (BHAP); phosphonoformic acid; 1,4-dihydro-2H-3,1-benzoxazin-2-ones NNRTIs, such as (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); or quinoxaline NNRTIs, such as isopropyl (2S)-7-fluoro-3,4-dihydro-2-ethyl-3-oxo-1(2H)-quinoxalinecarboxylate (HBY1293), wherein said additional agent is administered to said patient as either a separate dosage form or as a single dosage form together with said compound.

26. (Withdrawn) A method of treating a patient diagnosed with AIDS; AIDS related complex (ARC); progressive generalized lymphadenopathy (PGL); Kaposi's sarcoma, thrombocytopenic purpura; AIDS-related neurological conditions

Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice

such as AIDS dementia complex, multiple sclerosis or tropical paraperesis; anti-HIV antibody-positive conditions; or HIV-positive conditions, comprising the step of administering to said patient a composition according to claim 18.

27. (Withdrawn) The method according to claim 26, comprising the additional step of administering to said patient an additional therapeutic agent selected from (1 alpha, 2 beta, 3 alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine ((-)BHCG, SQ-34514); oxetanocin-G (3,4-bis-(hydroxymethyl)-2-oxetanosyl]guanine); acyclic nucleosides, such as acyclovir, valaciclovir, famciclovir, ganciclovir or penciclovir; acyclic nucleoside phosphonates, such as (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC); ribonucleotide reductase inhibitors, such as 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl] thiocarbonohydrazone, 3'-azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides such as 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, or 2',3'-didehydrothymidine; other aspartyl protease inhibitors, such as indinavir, ritonavir, nelfinavir, or [3S-[3R*(1R*, 2S*)]]-[3[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-tetrahydro-3-furanyl ester (amprenavir); oxathiolane nucleoside analogues, such as (-)-cis-1-(2-hydroxymethyl)-1,3-

Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice

oxathiolane 5-yl)-cytosine (lamivudine) or cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC); 3'-deoxy-3'-fluorothymidine; 5-chloro-2',3'-dideoxy-3'-fluorouridine; (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ribavirin; 9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G); tat inhibitors, such as 7-chloro-5-(2-pyrrolyl)-3H-1,4-benzodiazepin-2-(H)one (Ro5-3335) or 7-chloro-1,3-dihydro-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine (Ro24-7429); interferons, such as α -interferon; renal excretion inhibitors such as probenecid; nucleoside transport inhibitors such as dipyridamole; pentoxifylline; N-acetylcysteine (NAC); Procysteine; α -trichosanthin; phosphonoformic acid; immunomodulators, such as interleukin II or thymosin; granulocyte macrophage colony stimulating factors; erythropoietin; soluble CD₄ and genetically engineered derivatives thereof; non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine (BI-RG-587), loviride (α -APA) or delavuridine (BHAP); phosphonoformic acid; 1,4-dihydro-2H-3,1-benzoxazin-2-ones NNRTIs, such as (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); or quinoxaline NNRTIs, such as isopropyl (2S)-7-fluoro-3,4-dihydro-2-ethyl-3-

Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice

oxo-1(2H)-quinoxalinecarboxylate (HBY1293), wherein said additional agent is administered to said patient as either a separate dosage form or as a single dosage form together with said compound.

28. (Previously presented) The compound according to claim 15, wherein said compound is compound number 368.

29. (Previously presented) The composition according to claim 19, wherein said composition is in an orally available dosage form.

30. (Previously presented) The composition according to claim 20, wherein said composition is in an orally available dosage form.

31. (Previously presented) The composition according to claim 21, wherein said composition is in an orally available dosage form.

32. (Withdrawn) The method according to claim 24, comprising the additional step of administering to said patient an additional therapeutic agent selected from (1 alpha, 2 beta, 3 alpha)-9-[2,3-bis(hydroxymethyl)

Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice

cyclobutyl]guanine [(-)BHCG, SQ-34514]; oxetanocin-G (3,4-bis-(hydroxymethyl)-2-oxetanosyl]guanine); acyclic nucleosides, such as acyclovir, valaciclovir, famciclovir, ganciclovir or penciclovir; acyclic nucleoside phosphonates, such as (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC); ribonucleotide reductase inhibitors, such as 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl] thiocarbonohydrazone, 3'-azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides such as 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, or 2',3'-didehydrothymidine; other aspartyl protease inhibitors, such as indinavir, ritonavir, nelfinavir, or [3S-[3R*(1R*, 2S*)]]-[3[[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-tetrahydro-3-furanyl ester (amprenavir); oxathiolane nucleoside analogues, such as (-)-cis-1-(2-hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine (lamivudine) or cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC); 3'-deoxy-3'-fluorothymidine; 5-chloro-2',3'-dideoxy-3'-fluorouridine; (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ribavirin; 9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G); tat inhibitors, such as 7-chloro-5-(2-pyrrolyl)-3H-1,4-benzodiazepin-2-(H)one (Ro5-3335) or 7-chloro-1,3-dihydro-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine (Ro24-7429);

Appln. No. 10/691,333
Reply dated March 13, 2007
In response to February 12, 2007 Notice

interferons, such as α -interferon; renal excretion inhibitors such as probenecid; nucleoside transport inhibitors such as dipyridamole; pentoxifylline; N-acetylcysteine (NAC); Procysteine; α -trichosanthin; phosphonoformic acid; immunomodulators, such as interleukin II or thymosin; granulocyte macrophage colony stimulating factors; erythropoetin; soluble CD₄ and genetically engineered derivatives thereof; non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine (BI-RG-587), loviride (α -APA) or delavuridine (BHAP); phosphonoformic acid; 1,4-dihydro-2H-3,1-benzoxazin-2-ones NNRTIs, such as (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); or quinoxaline NNRTIs, such as isopropyl (2S)-7-fluoro-3,4-dihydro-2-ethyl-3-oxo-1(2H)-quinoxalinecarboxylate (HBY1293), wherein said additional agent is administered to said patient as either a separate dosage form or as a single dosage form together with said compound.

33. (New) A compound selected from compound numbers: 26, 27, 28, 29, 30, 31, 32, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 59, 60, 61, 62, 63, 71, 72, 73, 74, 75,

Appln. No. 10/691,333
Reply dated March 13, 2007
in response to February 12, 2007 Notice

201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212,
213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224,
225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236,
237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248,
249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260,
261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272,
273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284,
285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296,
297, 298, 299, 300, 301, 302, 303, 304, 305, 309, 310, 311,
312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323,
324, 326, 327, 329, 331, 332, 333, 334, 335, 336, 337, 338,
339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 351,
352, 353, 354, 355, 356, 357, 358, 359, 361, 364, 365, 366,
367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378,
379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390,
391, 392, 393, 394, 395, 396, 397 and 398.